Staff costs increased from €66.56 million to €71.49 million that included €846,000 in share-based payments.
The directors said Genzyme’s revenues increased due to the product mix and transfer prices across the group. The Sanofi-owned firm’s spend in R&D last year decreased from €8.2 million to €7.1 million while non-cash depreciation costs totalled €20 million.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: